CB-010 is under clinical development by Caribou Biosciences and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for B-Cell Non-Hodgkin Lymphoma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CB-010’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CB-010 is under development for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B cell lymphoma, high grade B cell lymphoma, transformed follicular lymphoma, follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma and acute lymphocytic leukemia (ALL). The therapy comprises of allogeneic, genetically engineered T cells which express a chimeric antigen receptor that targets cells expressing CD19. It is being developed based on chRDNA technology, involves adeno associated virus vector (AAV).
Caribou Biosciences overview
Caribou Biosciences is a biopharmaceutical company that develops genome-edited allogeneic cell therapies for the treatment of cancer. It is investigating CB-010, an allogeneic anti-CD19 CAR-T (chimeric antigen receptor-T) cell therapy for B cell non-Hodgkin lymphoma; CB-011 drug against relapsed or refractory multiple myeloma; and CB-012 to treat acute myeloid leukemia (AML). The company is also evaluating CB-020, an iPSC-derived CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences utilizes its proprietary chRDNA (CRISPR hybrid RNA-DNA) technology to develop genome-edited cell therapies by enabling improved genome-editing precision. It works in collaboration with AbbVie Inc, and The Leukemia & Lymphoma Society to research and develop CAR-T cell products. Caribou Biosciences is headquartered in Berkeley, California, the US.
For a complete picture of CB-010’s drug-specific PTSR and LoA scores, buy the report here.